RxDoctor Payments DataLook up a doctor →

Vandana Abramson, MD

Medical Oncology · Nashville, TNNPI 1154359602

Payments from drug & device makers

$2,984,708in general payments, 2019–2025

Across 361 payments — averaging $8267.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.2M
  • Pfizer$696K
  • Medivation LLC.$462K
  • Seagen Inc.$303K
  • Gilead$126K
  • Hoffmann-la Roche Limited$47K
  • plus $128K from 14 others
$4,310in research payments, 2019–2025

Across 3 payments — averaging $1436.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,984,708 in reported general payments places this provider in the 85th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,254
Medicare patients
111
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →